Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Metformin Withdrawal In Metabolic Syndrome (METMS)

16 juni 2026 bijgewerkt door: University of Castilla-La Mancha

Effects of 14-Day Metformin Withdrawal on OGTT-Derived Insulin Sensitivity in Adults With Metabolic Syndrome: A Randomized Controlled Trial

The goal of this clinical trial is to investigate how a short-term interruption of metformin treatment affects insulin sensitivity, glucose control, and metabolic flexibility in adults with metabolic syndrome who are taking metformin as part of their usual medical treatment. Temporary interruptions in metformin treatment may occur in real-life situations, such as missed doses, medication access problems, travel, or planned short-term discontinuation for clinical reasons. This study aims to understand whether stopping metformin for 14 days leads to rapid changes in glucose metabolism or whether the effects of previous metformin treatment may persist during a short period without the medication.

The main questions it aims to answer are:

Does stopping metformin for 14 days worsen glucose control or insulin sensitivity measured by oral glucose tolerance tests, HbA1c, and continuous glucose monitoring?

Does stopping metformin for 14 days affect metabolic flexibility, measured by indirect calorimetry during the oral glucose tolerance test?

Does stopping metformin for 14 days affect blood lipids, liver and inflammatory markers, red blood cell parameters, kidney function markers, fasting lactate levels, blood pressure, or heart rate?

Researchers will compare participants who stop metformin for 14 days with participants who continue their usual metformin treatment to see whether temporary metformin discontinuation affects insulin sensitivity, glucose control, metabolic flexibility, and other cardiometabolic markers.

Participants in the metformin discontinuation group will stop taking metformin for 14 days. They will attend study visits on day 0, day 4, day 7, and day 14. At each visit, they will complete an oral glucose tolerance test, have blood samples taken, and undergo indirect calorimetry measurements before and after the glucose drink. Blood pressure and heart rate will also be measured during the test. Participants will wear a continuous glucose monitor throughout the 14-day period to track glucose levels and help detect any potentially unsafe increase in blood glucose.

Participants in the usual-treatment group will continue taking metformin as prescribed. They will attend study visits on day 0 and day 14. At each visit, they will complete an oral glucose tolerance test, have blood samples taken, and undergo indirect calorimetry, blood pressure, and heart rate measurements during the test.

At the study visits, researchers will assess glucose and insulin responses, HbA1c, continuous glucose monitoring data, metabolic flexibility, blood lipid profile, liver and inflammatory markers, red blood cell parameters, kidney function markers, fasting lactate levels, blood pressure, and heart rate.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

28

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Diego Mora-Gonzalez, Msc.
  • Telefoonnummer: +34 634596243
  • E-mail: Diego.Mora@uclm.es

Studie Locaties

  • Spanje
    • Toledo
      • Toledo, Toledo, Spanje, 45071

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Currently treated with metformin as part of their usual medical care for at least 12 months before enrolment.
  • Diagnosis of metabolic syndrome according to established clinical criteria, based on the presence of at least three of the following components: increased waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure or antihypertensive treatment, and elevated fasting glucose or treatment for dysglycemia.
  • Stable metformin dose for at least 3 months before enrolment.
  • Willing and medically able to temporarily discontinue metformin for 14 days if assigned to the metformin discontinuation group.
  • Able and willing to undergo repeated oral glucose tolerance tests, venous catheter placement, repeated blood sampling, indirect calorimetry measurements, blood pressure measurements, and heart rate measurements.
  • willing to wear a continuous glucose monitoring device during the study period.
  • Preserved kidney function at baseline, defined as estimated glomerular filtration rate ≥60 mL/min/1.75 m² and urine albumin-to-creatinine ratio <30 mg/g, or values considered clinically acceptable by the study physician.
  • No previous history of clinically significant diabetes-related complications, including diabetic retinopathy, diabetic foot disease, severe peripheral neuropathy, or diabetic kidney disease.

Exclusion Criteria:

  • Diagnosis of type 1 diabetes.
  • Current treatment with insulin or other glucose-lowering medications.
  • Previous history of severe hypoglycemia, diabetic ketoacidosis, hyperosmolar hyperglycemic state, or other acute diabetes-related metabolic complications.
  • Uncontrolled diabetes or clinically unsafe glycemic status at screening, defined as HbA1c above 8.0 %, fasting plasma glucose above 160 mg/dl, or any other glycemic value considered unsafe by the study physician.
  • Known allergy or intolerance to materials used in the continuous glucose monitoring device, adhesive patches, venous catheter, or study procedures.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: METFOR WITHDRAW
Participants in this arm will stop their Metformin treatment for 14 days.
Gedragsmatig: Temporary Metformin Withdrawal
Participants assigned to this intervention will temporarily stop taking their usual metformin treatment for 14 days. During this period, participants will undergo oral glucose tolerance tests and blood sampling on day 0, day 4, day 7, and day 14. They will also wear a continuous glucose monitoring device throughout the 14-day period to monitor glucose levels during metformin discontinuation.
Actieve vergelijker: CONTROL
Participants in this arm will continue with their Metformin treatment for 14 days.
Gedragsmatig: Temporary Metformin Withdrawal
Participants assigned to this intervention will temporarily stop taking their usual metformin treatment for 14 days. During this period, participants will undergo oral glucose tolerance tests and blood sampling on day 0, day 4, day 7, and day 14. They will also wear a continuous glucose monitoring device throughout the 14-day period to monitor glucose levels during metformin discontinuation.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
HOMA-IR will be calculated from fasting plasma glucose and fasting insulin concentrations. Higher values indicate greater insulin resistance.
From enrolment to the end of the intervention, 14 days.
Change in Matsuda Insulin Sensitivity Index
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
The Matsuda Insulin Sensitivity Index will be calculated from glucose and insulin concentrations obtained during the oral glucose tolerance test. Higher values indicate greater whole-body insulin sensitivity.
From enrolment to the end of the intervention, 14 days.
Mean sensor glucose during the intervention period
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
Mean glucose concentration will be assessed using continuous glucose monitoring (CGM) during the 14-day intervention period.
From enrolment to the end of the intervention, 14 days.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in glycated hemoglobin
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
HbA1c will be measured in blood and reported as percentage of total hemoglobin.
From enrolment to the end of the intervention, 14 days.
Percentage of time in range assessed by continuous glucose monitoring
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
Time in range will be defined as the percentage of time with sensor glucose between 70 and 180 mg/dL during the 14-day intervention period.
From enrolment to the end of the intervention, 14 days.
Change in respiratory exchange ratio response during the oral glucose tolerance test
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
Respiratory exchange ratio (RER) will be assessed by indirect calorimetry during the oral glucose tolerance test. The response will be calculated using the pre-specified respiratory exchange ratio values obtained during the test.
From enrolment to the end of the intervention, 14 days.
Change in plasma triglycerides
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
Plasma triglyceride concentration will be measured in blood before each OGTT.
From enrolment to the end of the intervention, 14 days.
Change in total cholesterol
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
Total cholesterol concentration will be measured in blood before each OGTT.
From enrolment to the end of the intervention, 14 days.
Change in HDL-cholesterol
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
HDL-cholesterol concentration will be measured in blood before each OGTT.
From enrolment to the end of the intervention, 14 days.
Change in LDL-cholesterol
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
LDL-cholesterol concentration will be measured in blood before each OGTT.
From enrolment to the end of the intervention, 14 days.
Change in estimated glomerular filtration rate
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
The estimated glomerular filtration rate will be calculated from serum creatinine and reported in mL/min/1.73 m².
From enrolment to the end of the intervention, 14 days.
Change in serum creatinine
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
Serum creatinine concentration will be measured in blood before each OGTT.
From enrolment to the end of the intervention, 14 days.
Change in urinary albumin-to-creatinine ratio
Tijdsspanne: From enrolment to the end of the intervention, 14 days.
The urinary albumin-to-creatinine ratio will be measured in urine before each OGTT.
From enrolment to the end of the intervention, 14 days.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

University of Castilla-La Mancha

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

5 april 2026

Primaire voltooiing (Geschat)

30 juli 2026

Studie voltooiing (Geschat)

30 augustus 2026

Studieregistratiedata

Eerst ingediend

9 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 juni 2026

Eerst geplaatst (Werkelijk)

22 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

22 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

16 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • METMS

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Upon reasonable request

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren